Non-A Blood Type Is a Risk Factor for Poor Cardio-Cerebrovascular Outcomes in Patients Undergoing Dialysis

Area of Science:

• Cardiology
• Nephrology
• Hematology

Background:

• The association between ABO blood type and cardiovascular outcomes is complex and not fully understood, particularly in patients undergoing dialysis.
• Dialysis patients are at increased risk for cardio-cerebrovascular events, necessitating identification of modifiable and non-modifiable risk factors.

Purpose of the Study:

• To investigate the clinical impact of ABO blood type on cardio-cerebrovascular outcomes in patients undergoing hemodialysis.
• To determine if specific blood types are associated with a higher or lower incidence of major adverse cardiovascular and cerebrovascular events in this population.

Main Methods:

• A cohort study involving 365 hemodialysis patients.
• Primary endpoint defined as a composite of cardio-cerebrovascular events and cardio-cerebrovascular death.
• Multivariable Cox regression analyses and Kaplan-Meier curves were used to identify independent determinants and compare event incidence across blood types.

Main Results:

• Blood type A was independently associated with a reduced risk of the primary endpoint (Hazard Ratio: 0.46, 95% CI: 0.26-0.81, p = 0.007).
• Kaplan-Meier analysis revealed a significantly lower incidence of the primary endpoint in blood type A patients compared to non-A types (Log-rank p = 0.001).
• Independent determinants of the primary endpoint included blood type, age, antiplatelet/anticoagulation therapy, left ventricular ejection fraction (LVEF), and left ventricular mass index.

Conclusions:

• Hemodialysis patients with blood type A exhibit a more favorable cardio-cerebrovascular outcome profile compared to those with non-A blood types.
• ABO blood type is an independent determinant of cardio-cerebrovascular events in patients undergoing dialysis.
• Further research is warranted to elucidate the mechanisms underlying this observed association and its clinical implications.